Table 1.
Clinical characteristics of C‐SCLC and NC‐SCLC patients before and after matching
| Before matching | After matching | |||||
|---|---|---|---|---|---|---|
| Characteristics | C‐SCLC (n = 184) | NC‐SCLC (n = 2681) | P | C‐SCLC (n = 184) | NC‐SCLC (n = 552) | P |
| Age (years old) | 67.93 ± 10.04 | 67.74 ± 9.53 | 0.798 | 67.93 ± 10.04 | 68.71 ± 9.34 | 0.333 |
| Gender | 0.149 | 0.201 | ||||
| Female | 88 (47.8%) | 1437 (53.6%) | 88 (47.8%) | 296 (53.6%) | ||
| Male | 96 (52.2%) | 1244 (46.4%) | 96 (52.2%) | 256 (46.4%) | ||
| Race | 0.517 | 0.502 | ||||
| African‐American | 18 (9.8%) | 200 (7.5%) | 18 (9.8%) | 40 (7.2%) | ||
| Other | 8 (4.3%) | 119 (4.4%) | 8 (4.3%) | 21 (3.8%) | ||
| White | 158 (85.9%) | 2362 (88.1%) | 158 (85.9%) | 491 (88.9%) | ||
| Year of diagnosis | 2007 ± 5.74 | 2004 ± 6.86 | < 0.0001 | 2007 ± 5.74 | 2007 ± 6.05 | 0.751 |
| Marital status | 0.256 | 0.430 | ||||
| Married | 101 (54.9%) | 1456 (54.3%) | 101 (54.9%) | 295 (53.4%) | ||
| Separated† | 54 (29.3%) | 889 (33.2%) | 54 (29.3%) | 183 (33.2%) | ||
| Single | 19 (10.3%) | 255 (9.5%) | 19 (10.3%) | 57 (10.3%) | ||
| Unknown | 10 (5.4%) | 81 (3.0%) | 10 (5.4%) | 17 (3.1%) | ||
| Insurance‡ | N = 112 | N = 1147 | 0.215 | N = 112 | N = 335 | 0.037 |
| Insured | 96 (85.7%) | 953 (83.1%) | 96 (85.7%) | 280 (83.6%) | ||
| Medicaid | 11 (9.8%) | 159 (13.9%) | 11 (9.8%) | 49 (14.6%) | ||
| Uninsured | 5 (4.5%) | 24 (2.1%) | 5 (4.5%) | 3 (0.9%) | ||
| Unknown | 0 (0.0%) | 11 (1.0%) | 0 (0.0%) | 3 (0.9%) | ||
| Location | < 0.001 | 0.005 | ||||
| Upper lobe | 125 (67.9%) | 1466 (54.7%) | 125 (67.9%) | 321 (58.2%) | ||
| Middle lobe | 6 (3.3%) | 176 (6.6%) | 6 (3.3%) | 36 (6.5%) | ||
| Lower lobe | 50 (27.2%) | 817(30.5%) | 50 (27.2%) | 153 (27.7%) | ||
| Others | 3 (1.6%) | 222 (8.3%) | 3 (1.6%) | 42 (7.6%) | ||
| Grade | < 0.001 | < 0.001 | ||||
| Grade I/II | 13 (7.1%) | 45 (1.7%) | 13 (7.1%) | 13 (7.1%) | ||
| Grade III/IV | 125 (67.9%) | 1263 (47.1%) | 125 (67.9%) | 242 (43.8%) | ||
| Unknown | 46 (25.0%) | 1373 (51.2%) | 46 (25.0%) | 303 (54.9%) | ||
| Laterality | 0.796 | 0.830 | ||||
| Left | 84 (45.7%) | 1200 (44.8%) | 84 (45.7%) | 247 (44.7%) | ||
| Right | 100 (54.3%) | 1475 (55.0%) | 100 (54.3%) | 304 (55.1%) | ||
| Unilateral | 0 (0.0%) | 6 (0.2%) | 0 (0.0%) | 1 (0.2%) | ||
| Operation | 0.0005 | < 0.001 | ||||
| No surgery | 34 (18.5%) | 1850 (69.0%) | 34 (18.5%) | 402 (72.8%) | ||
| Lobectomy | 112 (60.9%) | 573 (21.4%) | 112 (60.9%) | 95 (17.2%) | ||
| Pneumonectomy | 3 (1.6%) | 25 (0.9%) | 3 (1.6%) | 4 (0.7%) | ||
| Sublobar | 35 (19.0%) | 233 (8.7%) | 35 (19.0%) | 51 (9.2%) | ||
| Chemotherapy | 102 (55.4%) | 2224 (83.0%) | < 0.0001 | 102 (55.4%) | 461 (83.5%) | < 0.001 |
| Radiation | 56 (30.4%) | 1621 (60.5%) | < 0.0001 | 56 (30.4%) | 357 (64.7%) | < 0.001 |
| Treatment | < 0.0001 | < 0.001 | ||||
| CTx | 10 (5.4%) | 443 (16.5%) | 10 (5.4%) | 80 (14.5%) | ||
| CRT | 14 (7.6%) | 1263 (47.1%) | 14 (7.6%) | 288 (52.2%) | ||
| RT | 10 (5.4%) | 144 (5.4%) | 10 (5.4%) | 34 (6.2%) | ||
| Surgery | 69 (37.5%) | 298 (11.1%) | 69 (37.5%) | 55 (10.0%) | ||
| Surgery + CTx | 49 (26.6%) | 319 (11.9%) | 49 (26.6%) | 60 (10.9%) | ||
| Surgery + CRT | 29 (15.8%) | 199 (7.4%) | 29 (15.8%) | 33 (6.0%) | ||
| Surgery + RT | 3 (1.6%) | 15 (0.6%) | 3 (1.6%) | 2 (0.4%) | ||
| T stage (8th edition TNM) | 0.077 | 0.889 | ||||
| T1a | 9 (4.9%) | 125 (4.7%) | 9 (4.9%) | 31 (5.6%) | ||
| T1b | 49 (26.6%) | 652 (24.3%) | 49 (26.6%) | 139 (25.2%) | ||
| T1c | 44 (23.9%) | 655 (24.4%) | 44 (23.9%) | 138 (25.0%) | ||
| T2a | 68 (37.0%) | 847 (31.6%) | 68 (37.0%) | 191 (34.6%) | ||
| T2b | 14 (7.6%) | 402 (15.0%) | 14 (7.6%) | 53 (9.6%) | ||
| T stage (2010–2014) | N = 69 | N = 729 | 0.999 | N = 69 | N = 105 | 0.807 |
| T1 | 40 (58.0%) | 422 (57.6%) | 40 (58.0%) | 129 (55.4%) | ||
| T2 | 29 (42.0%) | 309 (42.4%) | 29 (42.0%) | 104 (44.6%) | ||
| T stage (2005–2009) | N = 80 | N = 886 | 0.802 | N = 80 | N = 214 | 0.712 |
| T1 | 40 (50.0%) | 462 (52.1%) | 40 (50.0%) | 114 (53.3%) | ||
| T2 | 40 (50.0%) | 424 (47.9%) | 40 (50.0%) | 100 (46.7%) | ||
| T stage (1988–2004) | N = 35 | N = 1066 | 0.254 | N = 35 | N = 105 | 0.999 |
| T1 | 22 (62.9%) | 550 (51.6%) | 22 (62.9%) | 65 (61.9%) | ||
| T2 | 13 (37.1%) | 516 (48.5%) | 13 (37.1%) | 40 (38.1%) | ||
| N stage | 0.092 | 0.999 | ||||
| N0 | 144 (78.3%) | 1937 (72.2%) | 144 (78.3%) | 432 (78.3%) | ||
| N1 | 40 (21.7%) | 744 (27.8%) | 40 (21.7%) | 120 (21.7%) | ||
| Stage | 0.117 | 0.996 | ||||
| IA1 | 9 (4.9%) | 90 (3.4%) | 9 (4.9%) | 27 (4.9%) | ||
| IA2 | 40 (21.7%) | 486 (18.1%) | 40 (21.7%) | 110 (19.9%) | ||
| IA3 | 34 (18.5%) | 464 (17.3%) | 34 (18.5%) | 102 (18.5%) | ||
| IB | 49 (26.6%) | 610 (22.8%) | 49 (26.6%) | 157 (28.4%) | ||
| IIA | 12 (6.5%) | 287 (10.7%) | 12 (6.5%) | 36 (6.5%) | ||
| IIB | 40 (21.7%) | 744 (27.8%) | 40 (21.7%) | 120 (21.7%) | ||
| Stage (2010–2014) | N = 69 | N = 729 | N = 69 | N = 233 | ||
| I | 59 (85.5%) | 495 (67.9%) | 59 (85.5%) | 179 (76.8%) | ||
| II | 10 (14.5%) | 234 (32.1%) | 0.004 | 10 (14.5%) | 54 (23.2%) | 0.167 |
| Stage (2004–2009) | N = 80 | N = 886 | 0.999 | N = 80 | N = 214 | 0.250 |
| I | 57 (71.3%) | 629 (71.0%) | 57 (71.3%) | 168 (78.5%) | ||
| II | 23 (28.7%) | 257 (29.0%) | 23 (28.7%) | 46 (21.5%) | ||
| Stage (1988–2004) | N = 35 | N = 1066 | 0.748 | N = 35 | N = 105 | 0.999 |
| I | 28 (80.0%) | 812 (76.2%) | 28 (80.0%) | 84 (80.0%) | ||
| II | 7 (20.0%) | 254 (23.8%) | 7 (20.0%) | 21 (20.0%) | ||
†
Separated” includes divorce or widowed.
‡
Data available from the 2007 or later. CTx, chemotherapy; CRT, chemoradiation; RT, radiotherapy; TNM, tumor node metastasis.